Modification of amyloid-beta(1-40) by a protease inhibitor creates risk of error in mass spectrometric quantitation of amyloid-beta(1-42)

Anal Biochem. 2008 Nov 15;382(2):147-9. doi: 10.1016/j.ab.2008.07.033. Epub 2008 Aug 5.

Abstract

Matrix-assisted laser desorption mass spectrometry successfully analyzes mixed populations of amyloid-beta (Abeta) peptides, providing a profile in which changes caused by drug action are directly observed. A spectrum of Abeta immunocaptured from guinea pig brain included a novel component with monoisotopic [M+H]+ at 4511.22, close to the monoisotopic value of [M+H]+ for Abeta(1-42) of 4512.27 and overlapping and interfering with the authentic Abeta(1-42) peak. Hypothesis and experiment led to the conclusion that modification of Abeta(1-40) by the protease inhibitor aminoethylbenzenesulfonyl fluoride generates a product with monoisotopic [M+H]+ at 4511.19, and that this accounts for the interfering peak.

MeSH terms

  • Amyloid beta-Peptides / analysis
  • Amyloid beta-Peptides / chemistry*
  • Amyloid beta-Peptides / metabolism
  • Animals
  • Guinea Pigs
  • Molecular Weight
  • Peptide Fragments / analysis*
  • Peptide Fragments / chemistry*
  • Peptide Fragments / metabolism
  • Protease Inhibitors / pharmacology*
  • Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization*
  • Sulfones / pharmacology*

Substances

  • Amyloid beta-Peptides
  • Peptide Fragments
  • Protease Inhibitors
  • Sulfones
  • amyloid beta-protein (1-40)
  • amyloid beta-protein (1-42)
  • 4-(2-aminoethyl)benzenesulfonylfluoride